Clinical Trial: Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy

U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07675668) titled 'Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy' on June 16.

Brief Summary: The goal of this clinical trial is designed to characterise the safety, tolerability, efficacy, and PK of Aom0304 across oHCM and nHCM populations and to inform dose selection for future Phase 3 development. The main questions it aims to answer are:

1. Which dose is safe and tolerant of Aom0304 in participants with HCM?

2. Which dose is effective of 12 weeks of Aom0304 treatment in participants with oHCM or nHCM? Researchers will compare different doses of Aom0304 to see which works best. All participants will receive Aom0304, but at ...